Target chimeric antigen receptor t cell based immunotherapy. Medical search. Frequent questions

In current clinical development, targeting CD19 + B cell malignancies, which include acute and chronic B-cell leukaemia and B-cell non-Hodgkin lymphomas (NHLs), with anti-CD19 CAR-T cells is one of the most advanced adoptive T-cell therapies and has been approved by the FDA. (nature.com)
Despite their efficiency, adoptive T-cell therapies show unique toxicities, which are distinct from those seen with conventional chemotherapies, monoclonal antibodies (mAbs), and small-molecule-targeted therapies. (nature.com)
This collaboration with Medigene expands our cell therapy portfolio and TCR discovery capabilities, and further strengthens our ability to be a leader in the rapidly emerging field of engineered cell therapies," said Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech . (pressetext.com)
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. (pfizer.ca)
Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. (pfizer.ca)
Cilta-cel is an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy for the treatment of adults with relapsed or refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 antibody. (pharmiweb.com)
Medigene concentrates on the development of personalized T cell-based therapies with the focus on T cell receptor-modified T cells (TCR-Ts) and has projects currently in preclinical and clinical development. (medigene.com)
But under the new rules adopted by the Michigan Certificate of Need Commission, hospitals will need to go through unnecessary third-party accreditation processes before being able to offer CAR T-cell therapies. (reason.com)
In 2017, the Food and Drug Administration (FDA) approved two CAR T-cell therapies for children suffering from leukemia and for adults with advanced lymphoma. (reason.com)
Although the technology is still being developed and other uses of T-cell therapies are yet to be approved by the FDA, the Michigan CON Commission does not do medical testing. (reason.com)
Background CAR-based cell therapies are hampered by a lack of cell surface target proteins that are also good tumor-specific antigens. (bmj.com)
Currently, a combination of chemotherapy and immunotherapy drugs are used for treating HCL patients and these intense therapies often end up with severe side effects. (lls.org)
The Hairy Cell Leukemia Foundation (HCLF) and The Leukemia & Lymphoma Society (LLS) have joined forces to create the HCL2025 program to support targeted research to build a more comprehensive foundational understanding of the molecular basis of hairy cell leukemia (HCL), develop additional therapies, and optimize outcomes for patients with this disease. (lls.org)
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter ended June 30, 2023. (tmcnet.com)
These include personalized anti-cancer vaccines (dendritic cell based) and chimeric antigen receptor (CAR)-T cell therapies for gastrointestinal and hepatobiliary cancers. (mayo.edu)
By isolating immature and immunosuppressive cells from a patient's blood, transforming them into potent immune-stimulatory cells in the laboratory, and then injecting them back directly into the patient's bloodstream or tumor, these novel therapies have the potential to induce long-term tumor-specific durable responses. (mayo.edu)
Unfortunately, 40% of these patients don't respond to anti-epileptic drugs, meaning a better understanding of the biological mechanism is required to produce more targeted therapies. (axionbiosystems.com)
Chimeric antigen receptor (CAR) T-cell therapies have produced encouraging clinical outcomes, demonstrating their therapeutic potential in mitigating tumour development. (drugtargetreview.com)
Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful immunotherapeutic tools for combating hematological diseases confronted with pressing medical needs. (nature.com)
Lately, CAR-NK cell therapies have also come into focus as novel therapeutic options to address hurdles related to CAR-T cell therapies, such as therapy-induced side effects. (nature.com)
In this review, we are going to take a closer look at the commercial CAR-T cell therapies, as well as on CAR-T and CAR-NK cell products, which are currently under evaluation in clinical trials, that are being conducted in Germany. (nature.com)
However in the last years, immunotherapies using immune-checkpoint inhibitors (ICI), as well as cellular therapies, have moved into the limelight as promising alternative treatments. (nature.com)
Successful integration of my laboratory's bench-based and clinical correlative studies has led to multiple trials testing targeted therapies in children with high-risk leukemias, many of which I also lead or co-lead. (upenn.edu)
However, even with certain success in preclinical studies or in some specific types of cancer, large perspectives are unknown for these immunosuppressive cells, and the related therapies have undesirable outcomes for clinical patients. (bvsalud.org)
Cell therapies produced from the UDC line will not be rejected by a patient's immune system. (ca.gov)
As an early pioneer in cell therapies using dendritic macrophages to treat prostate cancer, Dr. William Haseltine now sees the immense potential for CAR T. In his latest book, he describes how CAR T cell therapy works, the potential and possibilities of integrating mRNA technology, current uses to treat cancer and ongoing efforts that adapt this system to treat other illnesses, including heart disease, HIV/AIDS and rheumatoid arthritis. (williamhaseltine.com)
Whether it involves cell, gene, or protein therapies, or cutting-edge biomechanical interventions, regenerative medicine is revolutionizing the healthcare landscape as we know it. (williamhaseltine.com)
B-cell targeted therapies have been around since the early 2000s with drugs like rituximab , a monoclonal antibody medication that targets CD20, an antigen expressed on the surface of B cells. (medscape.com)
Both are effective at depleting B cells in blood, but these engineered CD19-targeted T cells can reach B cells sitting in tissues in a way that antibody therapies cannot, Konig explained. (medscape.com)
June and his research team led the development of CAR T-cell therapies for blood cancers. (medscape.com)
Targeted molecular therapy, like therapy with monoclonal antibodies, gene therapy, and other therapies, has limited or nonexistent side effects on normal cells of the body, unlike present modalities such as surgery, chemotherapy, and radiotherapy. (medscape.com)
Targeted molecular therapy can also act as a complement to other existing cancer therapies. (medscape.com)

One way to achieve this is to genetically modify immune cells, mainly T cells and recently also natural killer (NK) cells, to express chimeric antigen receptors (CARs). (nature.com)
In this process, T cells are collected from patients via leukapheresis and then re-engineered to express chimeric antigen receptors. (medscape.com)

In oncology, we have presented encouraging data updates for our individualized mRNA cancer vaccine candidate BNT122 in pancreatic cancer and our novel CAR-T cell therapy candidate BNT211 in solid tumors, leading to our first PRIME designation by EMA. (yahoo.com)
The sale and licensing deal with BioNTech is an important validation from a global leading biotech company of our proprietary technologies to discover and characterize highly specific TCRs and empower resulting TCR-T cells to fight solid tumors. (pressetext.com)
In recent decades, monoclonal antibody-based treatment of cancer has been established as one of the most successful therapeutic strategies for both solid tumors and blood cancers. (asianscientist.com)
Treatment of syngeneic tumors resulted in CD8 and PD-L1-dependent tumor rejection or growth inhibition and a reduction in myeloid cells endogenously expressing high levels of PD-L1. (elifesciences.org)
MAINZ, Germany I September 9, 2022 I BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") today presented positive follow-up data from its ongoing first-in-human Phase 1/2 trial evaluating the safety and efficacy of the Company's novel CAR-T cell therapy candidate, BNT211, in patients with relapsed or refractory advanced solid tumors. (pipelinereview.com)
The product candidate recently received Priority Medicines (PRIME) designation by the European Medicines Agency (EMA) for the third- or later-line treatment of testicular germ cell tumors. (pipelinereview.com)
The designation was granted based on the encouraging initial data particularly in patients with testicular cancer which is the most common type of germ cell tumors. (pipelinereview.com)
It is a general experience that CAR T cell-based immunotherapy is not effective in eradicating solid tumors both in preclinical and clinical investigations. (hhs.gov)
The expression of PD-L1 and Ki67 in the tumors decreased and an increase in granzyme B levels was found in CAR T cells. (oncotarget.com)
These armed second-generation CAR T cells empowered to secrete human anti-PD-L1 antibodies in the ccRCC milieu to combat T cell exhaustion is an innovation in this field that should provide renewed potential for CAR T cell immunotherapy of solid tumors where limited efficacy is currently seen. (oncotarget.com)
One of the new emerging mechanisms associated with the progression of clear cell renal cell carcinoma (ccRCC) and other tumors is the immune checkpoint pathway, which consists of cellular interactions that prevent excessive activation of T cells under normal conditions. (oncotarget.com)
As an evasion mechanism, many tumors are able to stimulate the expression of immune checkpoint molecules, resulting in an exhausted phenotype of T cells that cannot restrain tumor progression [ 1 ]. (oncotarget.com)
Circulating tumor cells (CTCs) and incomplete surgical resection are the primary cause of distant metastasis and recurrence of tumors respectively. (bvsalud.org)
Targeted molecular therapy against EGFR has shown promise as an adjuvant therapy in preliminary studies in several solid tumors, including head and neck cancer. (medscape.com)

The collaboration brings together Amgen's commitment to and capabilities in advancing new approaches in immuno-oncology and Kite's industry-leading presence in CAR T cell therapy. (gilead.com)
Kite Pharma is an American biotechnology company that develops cancer immunotherapy products, with a primary focus on genetically engineered autologous CAR T cell therapy, a cell-based therapy which relies on chimeric antigen receptors and T cells. (wikipedia.org)
The acquisition was completed in October 2017, when Kite Pharma's Yescarta became the first CAR-T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. (wikipedia.org)
Axicabtagene ciloleucel (KTE-C19, ZUMA-3, YESCARTA) was an investigational therapy (for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL)) in which a patient's T cells were genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. (wikipedia.org)
It garnered a US FDA Breakthrough Therapy Designation (Dec 2015) for the treatment of patients with refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), and transformed follicular lymphoma (TFL). (wikipedia.org)
In January, Kite Pharma and Amgen entered into a strategic research collaboration and license agreement to develop and commercialize the next generation of novel Chimeric Antigen Receptor (CAR) T cell immunotherapies based on Kite's engineered autologous cell therapy platform and Amgen's extensive array of cancer targets. (wikipedia.org)
Adoptive cell therapy (ACT) with chimeric antigen receptor T (CAR-T) cells can restore the activity of exhausted T cell through reprogramming and is widely used in the treatment of relapsed/refractory (r/r) hematological malignancies. (hindawi.com)
Of note, CD19, CD20, CD30, CD33, CD123, and CD269 as ideal targets have shown extraordinary potential for CAR-T cell therapy and other targets such as CD23 and SLAMF7 have brought promising future for clinical trials. (hindawi.com)
Moreover, we will review the disadvantages of CAR-T cell therapy and propose several comprehensive recommendations which might guide its development. (hindawi.com)
In recent years, with the increased understanding of the molecular genetic basis of these malignancies, immune-targeted therapy has become a new possibility for the treatment of hematological malignancies. (hindawi.com)
T cell therapy has become a disruptive medical innovation in the treatment of patients with cancer. (pressetext.com)
In research published today in the journal Nature Communication s, the Utah-based scientists describe a novel way to treat cancers using chimeric antigen receptor (CAR) T cell therapy. (reachmd.com)
In CAR T cell therapy, doctors take T cells from a patient's blood and engineer them to recognize and attack cancer cells via an added "hook," called a CAR, that recognizes a surface molecule on cancer cells. (reachmd.com)
HCI researchers Tim Luetkens, MD, an expert in cell and protein engineering, and Sabarinath Radhakrishnan, MD, assistant professor of internal medicine at the U of U, led the development of the therapy in Atanackovic's lab. (reachmd.com)
AsianScientist (Dec. 7, 2017) - A team of researchers in Japan have developed a T cell therapy that specifically targets multiple myeloma cancer cells. (asianscientist.com)
One of the leading technologies to emerge in mAb-based treatment is chimeric antigen receptor T-cell (CAR-T) therapy. (asianscientist.com)
Today's submission is an encouraging step in our mission to provide a potentially transformative cell therapy option to patients with multiple myeloma," said Ying Huang, PhD, CEO and CFO of Legend Biotech. (pharmiweb.com)
Cilta-cel is an investigational chimeric antigen receptor T cell (CAR-T) therapy, formerly identified as JNJ-4528 in the U.S. and Europe and LCAR-B38M CAR-T cells in China, that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and in earlier lines of treatment. (pharmiweb.com)
Legend Biotech is a global, clinical-stage cell therapy company dedicated to treating, and one day curing, life-threatening diseases. (pharmiweb.com)
The candidate combines an autologous chimeric antigen receptor (CAR) T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) with a CLDN6-encoding CAR-T cell amplifying RNA vaccine (CARVac). (pipelinereview.com)
All of the patients had triple class-refractory disease, and 30% had prior exposure to therapy targeting B-cell maturation antigen (BCMA). (medpagetoday.com)
The 101 patients included in data analysis had received a median of six prior lines of therapy, and three-fourths of the patients had undergone stem-cell transplantation. (medpagetoday.com)
Immunotherapy is a type of biological therapy," explained David Eilender, MD , medical oncologist and hematologic specialist at Karmanos Cancer Institute at McLaren Flint . (karmanos.org)
Cell-based therapy , also known as T-cell transfer therapy requires the growth of immune cells outside of the body. (karmanos.org)
One example of this therapy is chimeric antigen receptor (CAR) T-cell therapy . (karmanos.org)
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. (ucl.ac.uk)
Usage of this 3D spheroid model for the evaluation of toxicity is a major building block for the effective development of highly innovative TCR-T cell therapy. (medigene.com)
TCR-T therapy is developed to utilize a higher number of potential tumor antigens than other T cell-based immunotherapies, such as chimeric antigen receptor T cell (CAR-T) therapy. (medigene.com)
Since one major limitation of CAR T cell-based therapy is represented by its potential toxicity and/or cytokine release syndrome, we have incorporated in our CAR construct an inducible caspase 9 safety switch which allows rapid elimination of CAR T cells in case of unexpected toxicities. (hhs.gov)
Anna Parsons, a policy coordinator with the American Legislative Exchange Council, points out that the safe administration of CAR T-cell therapy does not require hospitals to make new capital investments-which is the only time CON laws should apply. (reason.com)
Immune checkpoint inhibitors and adoptive T-cell therapy based on chimeric antigen receptors are the spearhead strategies to exploit the immune system to fight cancer. (cun.es)
This review describes the basics of mRNA biotechnology and provides insight into the recent advances in the use of mRNA for the local and systemic delivery of immunostimulatory antibodies, proinflammatory cytokines or for optimizing adoptive T-cell therapy. (cun.es)
Nkarta remains well positioned to advance allogeneic cell therapy and lead the development of groundbreaking natural killer cell therapy candidates," said Paul J. Hastings, President and CEO of Nkarta. (tmcnet.com)
Most CAR-T cell-based gene therapy products that are under clinical evaluation consist of autologous enriched T cells, whereas CAR-NK cell-based approaches can be generated from allogeneic donors. (nature.com)
Besides modification based on a second-generation CAR, more advanced CAR-immune cell therapeutics are being tested, which utilize precise insertion of genes to circumvent graft-versus-host disease (GvHD) or employ a dual targeting approach and adapter CARs in order to avoid therapy resistance caused by antigen loss. (nature.com)
The addition of separate adapter molecules (AMs) specific for tumor antigens and CAR-immune cells targeting these AMs allows a more precise and temporally limited therapy. (nature.com)
Thereby, several antigens can be targeted at once and the therapy can be adapted in case antigen-loss tumor variants appear. (nature.com)
An autologous CAR-T or NK cell therapy comprises several steps as shown in Fig. 1 . (nature.com)
Here, we developed a surgery-induced tumor metastasis model in immunocompetent mice to investigate the efficacy of CAR-T cells therapy in preventing metastasis and local recurrence. (bvsalud.org)
This study demonstrated that CAR-T cell therapy can be an adjuvant treatment following surgery to prevent tumor metastasis and inhibit primary tumor relapse for cancer patients. (bvsalud.org)
Thus, targeting these immunosuppressive cells and the related signals is the promising therapy to improve the efficacy of immunotherapies and reverse the immune resistance. (bvsalud.org)
Research Objective These studies will produce a new CAR-targeted iPSC-derived macrophage-based cell therapy product for treatment of refractory malignancies such as ovarian cancer. (ca.gov)
Research Objective The expected outcome is a therapeutic candidate, allogeneic HSC-engineered HLA-I/II-negative human iNKT cells, that can potentially be used as an off-the-shelf cellular therapy for treating cancer. (ca.gov)
Impact The proposed off-the-shelf HSC-engineered iNKT therapy has the potential to become a general cancer immunotherapy for treating multiple cancers and a large population of cancer patients. (ca.gov)
Research Objective Universal Pluripotent Liver Failure Therapy (UPLiFT) is composed of 2 lines- UPLiFT0 ( from LiPSC-GR1.1) and UPLiFT1 which will be derived from gene edited universal human pluripotent stem cells. (ca.gov)
Research Objective Development of hESC-derived pancreatic beta cells that are protected from allogeneic and autoimmune attack into a cell therapy for type 1 diabetes (T1D) Impact Cell therapy of T1D is challenged by immune rejection. (ca.gov)
Chimeric Antigen Receptor T cell therapy, commonly referred to as CAR T therapy, is a revolutionary cell-based immunotherapy treatment that breaks this mold. (williamhaseltine.com)
Allogeneic stem cell transplantation is the only known curative therapy for CLL. (medscape.com)
This cutting-edge application of cell-based immune therapy represents a further product candidate for Hemogenyx Pharmaceuticals in a new and exciting area of the treatment of blood cancers, and a potentially more benign and effective form of therapy that, if successful, would have a major impact on treatment and survival rates. (hemogenyx.com)
CAR-T therapy is a treatment in which a patient's own T cells, a type of immune cell, are modified to recognise and kill the patient's cancer cells. (hemogenyx.com)
Chimeric antigen receptor (CAR) T-cell therapy has offered a novel approach to treating hematologic cancers since 2017, but there are early signs that these cellular immunotherapies could be repurposed for B-cell mediated autoimmune diseases. (medscape.com)
In September of last year, researchers in Germany reported that five patients with refractory systemic lupus erythematosus (SLE) treated with CAR T-cell therapy all achieved drug-free remission. (medscape.com)
Since then, two biotechnology companies - Cabaletta Bio in Philadelphia and Kyverna Therapeutics in Emeryville, California - have already been granted fast-track designations from the US Food and Drug Administration for CAR T-cell therapy for SLE and lupus nephritis . (medscape.com)
The CAR T cells currently available target another surface antigen, CD19, and are a much more potent therapy. (medscape.com)
A few days before these modified T cells are infused back into the patient, the patients are given a low-dose chemotherapy (lymphodepletion) regimen to help increase the effectiveness of the therapy. (medscape.com)
[ 1 ] Early stage head and neck squamous cell carcinoma (HNSCC) is treated relatively well with single-modality therapy (either surgery or radiation alone). (medscape.com)
With the increased understanding of molecular mechanisms and basic pathways in the pathogenesis of squamous cell cancer of the head and neck , these pathways may be modified, and rational approaches in cancer therapy at the molecular level may be created. (medscape.com)
The goal of specific molecular targets in cancer therapy is to create a "magic bullet" that selectively kills cancer cells. (medscape.com)
Various techniques have been developed for targeting cancer cells: gene therapy, monoclonal antibodies (MAbs), antibody toxin conjugates, small-molecule inhibitors, antisense molecules, and tumor vaccines. (medscape.com)
The goal of gene therapy is to introduce new genetic material into cancer cells that selectively kills them without causing toxicity to the surrounding cells. (medscape.com)

The most active T cell endogenous inhibitory pathway is the immunoglobulin superfamily such as CD28/cytotoxic T lymphocyte antigen-4 (CTLA-4): B7-1/B7-2 receptor/ligand grouping, which plays a central role in coordinating immune responses [ 7 , 8 ]. (hindawi.com)
In this section, we will focus on NK cell immunotherapy, including the enhancement of antibody‐dependent cellular cytotoxicity, the manipulation of receptor‐mediated activation, inclusion criteria based on killer cell immunoglobulin‐like receptor (KIR) ligand mismatches, and adoptive immunotherapy with ex vivo expanded chimeric antigen receptor (CAR)‐engineered or engager‐modified NK cells. (intechopen.com)
Here, we describe the pre-clinical in vitro and in vivo study of irradiated haNK cells engineered to express a second-generation chimeric antigen receptor (CAR) targeting programmed death-ligand 1 (PD-L1). (elifesciences.org)
Methods CD56 + NK cells were selected from PBMCs, incubated with IL-15 and activated with a feeder free cocktail of an immobilized cytokine and activating ligand. (bmj.com)
We have developed a novel ligand based BAFF-CAR, that utilizes B cell activating factor (BAFF) as a ligand, which can bind to all three receptors of BAFF, which are expressed by malignant B cells including Hairy Cell Leukemia (HCL). (lls.org)
Herein we used a single bicistronic lentiviral vector to develop a new combination immunotherapy that consists of human anti-carbonic anhydrase IX (CAIX)-targeted chimeric antigen receptor (CAR) T cells engineered to secrete human anti-programmed death ligand 1 (PD-L1) antibodies at the tumor site. (oncotarget.com)
Selective compounds have been developed that target either the extracellular ligand-binding region of the EGFR (including a number of monoclonal antibodies [MAbs], immunotoxins, and ligand-binding cytotoxic agents) or the intracellular tyrosine kinase region (including various small-molecule inhibitors). (medscape.com)

Monoclonal antibodies (mAb), as the name implies, are antibodies that are made by clones derived from a single parent cell, and therefore share identical amino acid sequences. (asianscientist.com)
Classical " CARs consist of an extracellular binding domain mostly derived from a monoclonal antibody fragment (single-chain variable fragment-scFv), which is linked to intracellular binding domains of the T-cell receptor complex. (nature.com)
Non-Hodgkin lymphomas are a heterogeneous group of disorders involving malignant monoclonal proliferation of lymphoid cells in lymphoreticular sites, including lymph nodes, bone marrow, the spleen, the liver, and the gastrointestinal tract. (msdmanuals.com)
HEMO-CAR-T is made using Hemogenyx's proprietary humanised monoclonal antibody against a target on the surface of AML cells. (hemogenyx.com)

In June, Kite Pharma entered into an exclusive, worldwide license with the National Institutes of Health (NIH) to certain intellectual property related to TCR-based product candidates that target the NY-ESO-1 antigen for the treatment of cancers expressing NY-ESO-1. (wikipedia.org)
While UV1 implements specific amino acid chains representative of the human telomerase enzyme's (hTERT) reverse transcriptase subunit to help the native immune response target cancer cells, cancer vaccines that utilize mRNA technology have therapeutic potential in low-treatment option cancers, including many of those linked to occupational hazards. (biospace.com)
Immunotherapies that activate a patient's own immune system to fight their cancer have proven to be highly effective for many types of blood cancers. (reachmd.com)
Recent advances in our understanding of NK cell biology have paved the way for new therapeutic strategies based on NK cells for the treatment of various cancers. (intechopen.com)
However, many cancers are not yet amenable to immunotherapy. (standuptocancer.org)
Even for cancers for which immunotherapies exist, only a fraction of patients respond to such treatments. (standuptocancer.org)
Immunotherapies like the adoptive transfer of gene-engineered T cells and immune checkpoint inhibitors are novel therapeutic modalities for advanced cancers. (bvsalud.org)
In addition, cytokines and factors secreted by tumor cells or these immunosuppressive cells also mediate the tumor progression and immune escape of cancers. (bvsalud.org)
This is a new cell-based treatment for dogs with B cell cancers such as B cell lymphoma and B cell leukemia. (upenn.edu)
The CAR approach has shown promising results in people with blood cancers such as chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL), however, this is the first time that human CAR T cells will be used in canine patients. (upenn.edu)
The purpose of this study is to determine the safety, persistence and effectiveness of B cell specific UCART cells to target and kill B cells in dogs with B cell cancers. (upenn.edu)

Medigene will contribute its proprietary TCR discovery platform for the development of TCRs against multiple solid tumor targets nominated by BioNTech. (pressetext.com)
They will present innovative meth-ods for the evaluation of efficacy and toxicity of TCRs (T cell receptors) during the meeting that is scheduled to take place Friday, March 29 through Wednesday, April 3 in Atlanta, USA. (medigene.com)
We successfully applied this strategy to the human TAAs p53, gp100 and MDM2-specific TCRs as promising antigens-driven immunotherapy for both melanoma and hematologic malignancies. (unimedizin-mainz.de)

Recent advances in flow cytometric and molecular measurable residual disease detection have further enhanced modern risk-stratified approaches to chemotherapy and allocation to allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission (CR1) when indicated. (haematologica.org)

Immunotherapy based on the adoptive transfer of ex vivo expanded and activated autologous tumor-reactive lymphocytes can mediate tumor regression in cancer patients. (unimedizin-mainz.de)

2020. Target-Mediated Drug Disposition-A Class Effect of Soluble Epoxide Hydrolase Inhibitors. (ucdavis.edu)
In this webinar, Prof. Christopher F. Basler (Georgia State University) , identifies two small molecule inhibitors of VPS34, an enzyme involved in cell membrane dynamics, as well as two inhibitors of lipid metabolism, that can suppress SARS-CoV-2 virus replication in human cells in vitro . (axionbiosystems.com)
My laboratory has particular expertise in preclinical evaluation of small molecule inhibitors and CAR T cells in ALL and AML patient-derived xenograft models, as well as in phosphosignaling analyses and measurement of patients' molecular responses to targeted inhibitors. (upenn.edu)

We were dismayed that although some of our patients respond quite well to currently available immunotherapies, they relapsed as early as one year after treatment," says Atanackovic. (reachmd.com)
This approach is unique in that it is distinct from the vast majority of ongoing studies that are focused on modifying or optimizing currently available immunotherapies. (standuptocancer.org)

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. (ucl.ac.uk)

Traditionally, the treatment of hematological malignancies is administrated by chemotherapy, radiotherapy, and stem cell transplantation. (hindawi.com)
Peripheral T cell lymphomas (PTCLs) are generally chemotherapy resistant and have a poor prognosis. (mdpi.com)
Those treatments attempt to program the body's own immune system to attack and kill cancer cells, and they have become an increasingly attractive way to combat cancer alongside more traditional methods , such as surgery, chemotherapy, and radiation. (reason.com)
Your dog will receive chemotherapy prior to infusion and then will receive a single dose of UCART-20 cells that will be infused into your dog by an intravenous infusion (into a vein). (upenn.edu)

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study's primary efficacy endpoints. (pfizer.com)
Despite reports of clinical efficacy, the application of NK cell immunotherapy is limited. (intechopen.com)
The submission is based on results from the Phase 1b/2 CARTITUDE-1 study conducted in the US and Japan, which evaluated the efficacy and safety of cilta-cel for patients with relapsed or refractory multiple myeloma. (pharmiweb.com)
FDA's guidance and criteria are based on the scientific and medical principles necessary to clearly demonstrate the safety and efficacy of potential COVID-19 vaccines. (azbio.org)
The authors, scientists at Medigene, describe the use of 3D spheroids generated from tumor cell lines for assessment of TCR efficacy or healthy cells for evaluation of potential TCR-derived toxicity. (medigene.com)
Anti-tumor efficacy of CIR-NK cells in vitro. (bmj.com)
Continuous advances in the delivery and construction of RNA-based vectors hold promise for improvements in clinical efficacy. (cun.es)
An approach that targets multiple essential processes of tumorigenesis can overcome tumor-associated plasticity, clonal evolution and adaptive resistance, all of which limit the durable efficacy of current treatments. (mayo.edu)
Chimeric antigen receptors (CAR)-engineered T cells have demonstrated remarkable efficacy in patients with B-cell malignancies. (unimedizin-mainz.de)
Cancer immunotherapy has demonstrated remarkable efficacy by checkpoint modulation in a large variety of neoplasms. (unimedizin-mainz.de)

Genetically engineered T cells expressing a chimeric antigen receptor (CAR) are rapidly emerging a promising new treatment for haematological and non-haematological malignancies. (nature.com)
Although a strong response was observed for CAR-T cells in patients with treatment-refractory haematologic malignancies, only modest outcomes have been reported in solid tumours. (nature.com)
Kite Pharma announced findings from its ongoing clinical trial in August: 12 of 13 evaluable patients with advanced B-cell malignancies had complete remissions (8 patients) or partial remissions (4 patients) resulting in a 92% objective response rate. (wikipedia.org)
T cell immune protection plays a pivotal role in the treatment of patients with hematological malignancies. (hindawi.com)
However, T cell exhaustion might lead to the possibility of immune escape of hematological malignancies. (hindawi.com)
However, CAR-T cells can also produce some adverse events after treatment of hematological malignancies, such as cytokine release syndrome (CRS), neurotoxicity, and on-target/off-tumor toxicity, which may cause systemic immune stress inflammation, destruction of the blood-brain barrier, and even normal tissue damage. (hindawi.com)
It is noted that T cell has great potential for immunotherapy of hematological malignancies. (hindawi.com)
In addition, the isolation and storage of umbilical cord blood hematopoietic stem cells have been used to rebuild the immune system for the treatment of hematological malignancies and might be promising for the dynamic equilibrium expansion of functional T cells [ 12 ]. (hindawi.com)
Natural killer (NK) cells are an essential component of the innate immune system, and they play a crucial role in immunity against malignancies. (intechopen.com)
Chimeric antigen receptor T cells for gamma-delta T cell malignancies. (ucl.ac.uk)
The lack of targeted immunotherapeutic approaches for T cell malignancies results in part from potential risks associated with targeting broadly expressed T cell markers, namely T cell depletion and clinically significant immune compromise. (mdpi.com)

Adoptive cellular immunotherapy. (mayo.edu)
The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. (oncotarget.com)
Previous work from the contributing DKTK partner sites has demonstrated the versatility of this approach in T cells, and showed that it is feasible to derive CAR-engineered, established human NK cells as an off-the-shelf cellular therapeutic. (unimedizin-mainz.de)
Then, the immune system reboots, and now it's working, whereas before it was messed up," said Carl June, MD , who directs the Center for Cellular Immunotherapies at the at the University of Pennsylvania's Perelman School of Medicine. (medscape.com)

HLA-G directs immunosuppression by binding to ILT receptors (ILT2 in lymphoid cells and ILT4 in myeloid cells) via ITIM signaling domains. (bmj.com)
Hairy Cell Leukemia (HCL) is is an uncommon lymphoid neoplasm characterized by the accumulation of small mature B cell lymphoid cells with abundant cytoplasm and "hairy" projections within the peripheral blood, bone marrow, and splenic red pulp. (lls.org)

T cell-based immunotherapy, such as immune checkpoint blockade or adoptive T cell transfer, is limited by the ability of T cells to detect major histocompatibility complex (MHC)-presented antigen by tumor cells. (elifesciences.org)

NK cells express germ-line receptors that are either stimulatory or inhibitory, and the summation of these signals determines activation status ( Caligiuri, 2008 ). (elifesciences.org)

The vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer. (businesswire.com)
COMIRNATY and COMIRNATY Original & Omicron BA.4/BA.5, which are based on BioNTech's proprietary mRNA technology, were developed by both BioNTech and Pfizer. (pfizer.ca)
To take advantage of the full potential of the immune system, cancer immunotherapy must incorporate new biotechnologies such as mRNA technology that may synergize with already approved immunotherapies and act more effectively on immune targets. (cun.es)

Importantly, CD229 is also present on myeloma stem cells, which are the source of treatment-resistant tumor cells in patients who relapse. (reachmd.com)
In the current study, the authors observe the presence of circulating tumor cells in patients undergoing surgical resection of osteosarcoma which is correlated to tumor recurrence. (bvsalud.org)

PD-L1 CAR haNKs reduced levels of macrophages and other myeloid cells endogenously expressing high PD-L1 in peripheral blood from patients with head and neck cancer. (elifesciences.org)
Immunosuppressive cells such as myeloid-derived suppressive cells, tumor-associated macrophages, tumor-associated neutrophils, regulatory T cells (Tregs), and tumor-associated dendritic cells are critical factors correlated with immune resistance. (bvsalud.org)
Human iPSC-derived chimeric antigen receptor expressing macrophages for improved cancer treatment. (ca.gov)

Cancer vaccines are not a new idea: whether the vaccine is preventative, or one part of a multi-factor immunotherapy regimen, packaging treatments behind a viral mask has many potentially alluring benefits. (biospace.com)
According to the American Cancer Society (ACS), immunotherapy vaccines are used to fight a disease that already exists within the body. (karmanos.org)
The vaccines can also be made from the patient's immune cells and combined with the previous listed ingredients. (karmanos.org)
MAINZ, Germany, October 26, 2021 - BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Company plans to initiate the construction of the first state-of-the-art manufacturing site for mRNA-based vaccines in the African Union in mid-2022. (biontech.de)
The parties agree to jointly establish end-to-end manufacturing capacities for mRNA-based vaccines in Africa starting immediately. (biontech.de)
The success of mRNA-based COVID-19 vaccines has highlighted the feasibility of this approach. (cun.es)
The acquisition supports BioNTech's strategy, aiming to build world-leading capabilities in AI-driven drug discovery and development of next-generation immunotherapies and vaccines to address diseases with high unmet medical need. (gcs-web.com)

With our existing immuno-oncology portfolio of cutting-edge technologies and expertise, we believe joining forces with Kite Pharma will leverage our targets and their leading CAR T cell platform to advance another new promising therapeutic approach to fight cancer. (gilead.com)
Prior to infusion of the CAR-modified immune cells, lymphodepletion is performed in most therapeutic settings to allow efficient cell engraftment [ 10 ]. (nature.com)
In this review, we comprehensively summarized the phenotype, function, and potential therapeutic targets of these immunosuppressive cells in the tumor microenvironment. (bvsalud.org)
Impact Providing the immediate cell therapeutic candidate for clinical trial of diabetic patients. (ca.gov)
Here, we evaluated the safety issues raised by the risk of TAA-TCR gene transfer-associated on/off-target toxicities and the therapeutic potential in relevant transgenic mouse models of adoptive transfer. (unimedizin-mainz.de)

Concurrently, the myeloma field is being revolutionized by immunotherapies, such as bispecific antibodies and chimeric antigen receptor T cells," he noted. (medpagetoday.com)

They engineered the first fully human antibody against CD229 and, with this newly engineered "hook," produced CAR T cells targeting CD229. (reachmd.com)
If you have a patient with myositis, for example, where autoreactive B cells are sitting in the inflamed muscle, or a patient with rheumatoid arthritis , where you have disease-relevant B cells in hard-to-reach tissues like the synovium, those cells are much harder to deplete with an antibody, compared to a T cell that evolved to surveil and effectively kill in all tissues," he explained. (medscape.com)

MMG49 binds to a subset of integrin β7, which are cell-surface proteins that allow cells to attach to surfaces. (asianscientist.com)
Therefore, it is highly plausible that there are other cancer immunotherapeutic targets that have yet to be identified among the many cell-surface proteins that undergo conformational changes, even if the expression of the proteins themselves is not cancer-specific. (asianscientist.com)
The journey of figuring out how to use the immune system to treat cancer started in the late 1800s, and now two centuries later, immunotherapy - a treatment that enhances the body's complex network of cells and proteins - is emerging as one of the newer forms of cancer treatment. (karmanos.org)
They are often made of cancer cells, parts of cancer cells, or proteins that are on the cancer cells. (karmanos.org)
T cells (blue), part of the body's immune system, are taken from the patient and have their DNA (deoxyribonucleic acid) modified by viruses (spiky spheres) so that they produce chimeric antigen receptor (CAR) proteins. (reason.com)
Activated NK cells were transduced with γ-retroviruses directing expression of CIR proteins, soluble IL-15 and a ΔCD19 marker protein or CAR control constructs directed to HLA-G or CD33. (bmj.com)

Moreover, CAR-T cells are vulnerable to immunosuppressive mechanisms. (nature.com)
Thus, addressing the presence of immunosuppressive myeloid cell populations in the periphery and tumor microenvironment of patients with cancer is likely to be required for effective NK cell-based immunotherapy. (elifesciences.org)
Conclusions This technology takes advantage of the physiological pairing of the ILT receptors with the multiple immunosuppressive HLA-G isoforms. (bmj.com)

Failed T cell-based immunotherapies in the presence of genomic alterations in antigen presentations pathways may be overcome by NK cell-based immunotherapy. (elifesciences.org)
[ 3 ] In an attempt to improve outcomes in HNSCC, most research in the field is now focusing on the molecular biology of HNSCC in an attempt to target select pathways involved in carcinogenesis. (medscape.com)
Some of the new approaches depend on tumor biology and aim specifically to inhibit tumor growth and metastasis by targeting the tumor microenvironment or vasculature (leaving normal cells unaffected) or focusing on specific protein or signal transduction pathways. (medscape.com)

Removing senescent T cells from the physiological cycle to maintain the homeostasis of memory and effector T cells is the way of replacement. (hindawi.com)

Despite the success of Chimeric antigen receptor T cell (CAR-T) immunotherapies, disease relapse occurs in a majority of patients. (lls.org)
In addition, the local relapse was obviously inhibited at the surgical site followed by EpCAM-CAR-T cell treatment. (bvsalud.org)
With few exceptions, stem cell transplantation is usually reserved for patients with aggressive lymphomas after incomplete remission or relapse. (msdmanuals.com)

Various biological processes including immunoreaction of infection, tumor prevention, and human aging could cause telomere damage, tumor-related stress responses, and T regulatory (Treg) cells activation, which even trigger T cell senescence showing the distinctive phenotypic and functional alternation [ 9 , 10 ]. (hindawi.com)
We thought if we could target every last cancer cell in a patient's body, including the cancer stem cell, this could make the critical difference and yield more durable, deeper responses to treatment. (reachmd.com)
Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients. (ucl.ac.uk)

Mainz/Martinsried/Munich, Germany, 21 February 2022 - BioNTech SE (Nasdaq: BNTX, "BioNTech") and Medigene AG (FSE: MDG1, Prime Standard, "Medigene"), a clinical-stage immuno-oncology company focusing on the development of T cell immunotherapies, today announced that they have entered a multi-target research collaboration to develop T cell receptor (TCR) based immunotherapies against cancer. (pressetext.com)
BioNTech will acquire Medigene's next generation preclinical TCR program, which combines TCR-4 of Medigene's MDG10XX program targeting PRAME with Medigene's proprietary PD1-41BB switch receptor technology. (pressetext.com)
Health Canada's authorization is based primarily on the clinical trial data filed by Pfizer and BioNTech. (pfizer.ca)
Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. (pfizer.ca)
BioNTech plans to develop and implement a scalable construction network based on the expertise and learnings from the ramp-up of the Company's production facility in Marburg. (biontech.de)
BioNTech will initially staff, own and operate the facility to support the safe and rapid initiation of the production of mRNA-based vaccine doses. (biontech.de)
InstaDeep will operate as a UK-based global subsidiary of BioNTech. (gcs-web.com)
The total consideration to acquire the remaining InstaDeep shares, excluding the shares already owned by BioNTech, amounts to approximately €500 million in cash, BioNTech shares, and performance-based future milestone payments. (gcs-web.com)

Compared with CAR-T cells, CAR exosomes do not express Programmed cell Death protein 1 (PD1), and their antitumour effect cannot be weakened by recombinant PD-L1 treatment. (nature.com)
In this review, we aim to summarize the composition of CAR-T cell and its application in the treatment of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL), multiple myeloma (MM), and acute myeloid leukemia (AML). (hindawi.com)
Reprogramming is a promising treatment, which redifferentiates T-induced pluripotent stem cells (T-IPSCs) into naïve and cytotoxic T cells or dedifferentiates within their own lineage [ 13 ]. (hindawi.com)
This grim reality motivated researchers at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) to try to improve the depth and durability of treatment response in multiple myeloma through a new cancer cell targeting mechanism. (reachmd.com)
The landscape of relapsed pediatric AML treatment is changing rapidly, however, as the international AML community harnesses collective knowledge and resources to characterize the genetic and immunophenotypic heterogeneity of relapsed disease, identify biological targets of interest within specific AML subtypes, develop new precision medicine approaches for collaborative investigation in early-phase clinical trials, and tackle challenges of universal drug access across the globe. (haematologica.org)
Mezigdomide targets cereblon, the long-sought binding partner for thalidomide, which failed notoriously as a sedative for use during pregnancy but found a home as the first highly active treatment for myeloma. (medpagetoday.com)
Therefore, after having shown that B7-H3 CAR T cells can recognize and eliminate UM cells surviving the treatment with the MEKi and HDACi combination, we will investigate whether tumor debulking induced by the MEKi and HDACi combination can enhance the ability of B7-H3 CAR T cells to eradicate UM liver metastases in NSG mice. (hhs.gov)
Epoxy Fatty Acids Are Promising Targets for Treatment of Pain, Cardiovascular Disease and Other Indications Characterized by Mitochondrial Dysfunction, Endoplasmic Stress and Inflammation. (ucdavis.edu)
In Dr. Haseltine's career at the forefront of medical research and application, he has educated a generation of doctors at Harvard Medical School, designed the strategy to develop the first treatment for HIV/AIDS, is well known for his groundbreaking work on cancer, and led the team that pioneered the development of new drugs based on information from the human genome. (williamhaseltine.com)
This multi-center (Müchen, Heidelberg, Frankfurt/Mainz, Essen, Freiburg, Dresden, Berlin) project will provide a better understanding of the interplay between mutational signatures and the relevant components of the immune system aiming at biomarker discovery and the design of combinatorial treatment strategies based on the identified mechanisms of action. (unimedizin-mainz.de)
Hemogenyx Pharmaceuticals has constructed Chimeric Antigen Receptor (CAR) programmed T cells, termed HEMO-CAR-T, for the potential treatment of Acute Myeloid Leukemia (AML). (hemogenyx.com)
This type of treatment is known as adoptive immunotherapy and the cells that are infused into the patients are known as universal chimeric antigen receptor T cells (UCAR T cells). (upenn.edu)

mRNA-based nanomedicines have great potential to expand the arsenal of immunotherapy tools due to their ability to simplify and accelerate drug development and their suitability for transient and local expression of immunostimulatory molecules, whose systemic and sustained expression would be toxic. (cun.es)
For most of modern medicine, cancer drugs have been developed the same way: by designing molecules to treat diseased cells. (williamhaseltine.com)
Promising combinations of UniCAR NK cells and distinct targeting molecules will be identified for subsequent translation into a phase clinical study. (unimedizin-mainz.de)

In December, the company announced data in its lead clinical development program with the NCI, demonstrating that Kite's most advanced immunotherapy product candidate - KTE-C19 CAR - can produce robust and durable tumor shrinkage in patients with an aggressive form of non-Hodgkin's lymphoma, known as diffuse large B cell lymphoma (DLBCL). (wikipedia.org)
The results support Kite Pharma's plan to file an Investigational New Drug (IND) application in the fourth quarter of 2014 to initiate a clinical trial of Kite Pharma's lead CAR-based product candidate, KTE-C19, in patients with DLBCL. (wikipedia.org)
A poster detailing the Phase I/II clinical trial for this asset was presented in a late-breaking session at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). (biospace.com)
The authorization of COMIRNATY Original & Omicron BA.4/BA.5 is based on clinical data from Pfizer and BioNTech's Monovalent ("original" vaccine), Omicron BA.1-adapted bivalent vaccine as well as pre-clinical and manufacturing data from their Omicron BA.4/BA.5-adapted bivalent vaccine. (pfizer.ca)
the resulting unfavorable effector to target (E:T) ratio in the tumor microenvironment has a negative impact on the antitumor activity of CAR T cells, as indicated by the results generated by preclinical and clinical investigations. (hhs.gov)
In June 2023, Nkarta presented preliminary clinical data based on a November 2022 data cut-off from its Phase 1 dose escalation clinical trial of NKX019 in patients with relapsed or refractory non-Hodgkin lymphoma (NHL) at two scientific meetings: an oral presentation at the annual meeting of the European Hematology Association (EHA) and an encore poster presentation at the International Conference on Malignant Lymphoma (17-ICML). (tmcnet.com)
Nkarta is evaluating the potential for clinical development of NKX019 in non-malignant, B-cell mediated disease. (tmcnet.com)
It is hoped that these cells will kill your dog's B cells, reduce tumor burden and induce clinical remission. (upenn.edu)
The pathophysiology of SLE has not been defined fully, although many genes that affect immune function, particularly the human leukocyte antigen (HLA), may augment susceptibility to clinical disease. (medscape.com)

Immunotherapy biomarkers. (mayo.edu)
These immunotherapy biomarkers would ultimately help risk stratify patients and optimize the timing and design of combinatorial approaches. (mayo.edu)
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy. (cdc.gov)

This family, which includes epidermal growth factor receptor (EGFR), plays a pivotal role in normal cell growth, lineage determination, repair, and functional differentiation. (medscape.com)

Natural killer (NK) cell-based immunotherapy may overcome genetic mechanisms of resistance to T cell-based immunotherapy through antigen- and MHC-independent recognition of malignant cells. (elifesciences.org)
Normally, potentially malignant cells are continuously eliminated by the immune system, but cancer cells can accumulate certain mutations, which allow them to escape these mechanisms [ 2 ]. (nature.com)
CAR-modified immune cells are expanded until sufficient cell numbers are attained and are adoptively transferred into the patient to fight malignant cells. (nature.com)
Hodgkin Lymphoma Hodgkin lymphoma is a localized or disseminated malignant proliferation of cells of the lymphoreticular system, primarily involving lymph node tissue, spleen, liver, and bone marrow. (msdmanuals.com)

Kite will be responsible for conducting all preclinical research and cell manufacturing and processing through Investigational New Drug (IND) filing. (gilead.com)

The study builds on earlier work by Atanackovic and his colleagues in which they identified CD229 as present on multiple myeloma and other B cell cancer cells. (reachmd.com)
They confirmed their hypothesis CD229 CAR T kills mature multiple myeloma cells, as well as myeloma stem cells, using a mouse model, as well as stem cells derived from myeloma patients. (reachmd.com)
In this study, the researchers at Osaka University screened more than 10,000 mAb clones and identified a mAb that specifically recognizes multiple myeloma (MM) cells, calling it MMG49. (asianscientist.com)
Multiple myeloma, an incurable blood cancer that starts in the bone marrow and is characterized by an excessive proliferation of plasma cells. (pharmiweb.com)

In June, Kite Pharma and bluebird bio, Inc. announced they have entered into a collaboration agreement to co-develop and co-commercialize second generation T cell receptor product candidates directed against the human papillomavirus type 16 E6 onco protein incorporating gene editing and lentiviral technologies. (wikipedia.org)
Our results demonstrate that the active conformer of integrin β7 can serve as an immunotherapeutic target against MM, even though the expression of the protein itself is not specific to MM," said study coauthor Dr. Yukiko Matsunaga of the University of Tokyo. (asianscientist.com)
Because the Omicron BA.4 and BA.5 variants contain identical spike protein amino acid sequences, both can be targeted with a single mRNA strand. (pfizer.ca)
BAFF is a protein which can bind to this receptor and helps the survival of mature B cells. (lls.org)

Although mezigdomide is active in cells with low levels of cereblon, it cannot work in the complete absence of cereblon or overcome cereblon-independent resistance mechanisms," Shortt continued. (medpagetoday.com)
A key area of Dr. Kankeu Fonkoua's research endeavors is to identify mechanisms of resistance to immunotherapy. (mayo.edu)
We compared these studies based on the antibiotic used and differential impacts on gut bacteria, i.e., gut microbiome profiles and/or resistance genes. (cdc.gov)

The pulmonary infiltrations of neutrophils and Gr-1+ myeloid cells are characterized to form a pre-metastatic niche upon the exposure of circulating tumor cells after surgical resection. (bvsalud.org)

Here, we report that CAR-T cells release extracellular vesicles, mostly in the form of exosomes that carry CAR on their surface. (nature.com)
Typically, CARs consist of a target binding domain, which is an extracellular domain that is specifically expressed by CAR-T cells, a transmembrane domain, and a signalling domain, which is an intracellular domain that provides an activation signal to T cells. (nature.com)
A) Schematic depiction of a CIT comprising the extracellular D1 and D2 domains of ILT2, a stalk and transmembrane domain derived from CD8-α and a replacement of the ITIM domains of ILT2 with engineered signalling domains driving NK cell activation. (bmj.com)
B,C) 7-day Co-culture of Kasumi1-GFPffluc (B) or Molm13-GFPffluc AML cells with mock-transduced (Mock) NK cells or NK cells transduced to express CIRs containing the D1-D4 extracellular domains (CIR3) or only the D1-D2 domains (CIR4) from ILT2 or ILT4. (bmj.com)

Binding of a tumor antigen via the scFv activates the T cell in a major histocompatibility-independent manner which leads to a cytotoxic response [ 3 ]. (nature.com)

Cancer immunotherapies aim to support or boost the patient's immune system to enable the effective clearance of cancer cells. (nature.com)

Anatomy26

Organisms11

Diseases9

Chemicals and Drugs102

Analytical, Diagnostic and Therapeutic Techniques and Equipment29

Psychiatry and Psychology1

Phenomena and Processes39

Technology, Industry, Agriculture1

Information Science3

Health Care1

Therapies32

Express chimeric antigen receptors2

Tumors14

Therapy60

Ligand7

Monoclonal4

Cancers11

TCRs3

Allogeneic hematopoietic stem c1

Autologous1

Inhibitors3

Currently available immunotherapies2

CD191

Chemotherapy4

Efficacy10

Malignancies11

Cellular4

Lymphoid cells2

Checkpoint1

Inhibitory1

MRNA technology3

Tumor cells in patients2

Macrophages3

Vaccines7

Therapeutic5

Bispecific1

Antibody2

Proteins6

Immunosuppressive3

Pathways3

Effector T cel1

Relapse3

Responses3

BioNTech8

Treatment12

Molecules3

Clinical9

Biomarkers3

Plays a pivotal role1

Malignant4

Preclinical1

Multiple myeloma4

Protein4

Resistance3

Myeloid cells1

Extracellular4

ScFv1

Patient's immune1